IBEXIS LIFE & ANNUITY INSURANCE COMPANY – Trademark Portfolio
Entity Type: 03
IBEXIS LIFE & ANNUITY INSURANCE COMPANY holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 6 filings in this category. Currently, 6 trademarks are registered. Notable registered marks include IBEXIS, IBEXIS FIA PLUS, IBEXIS WEALTHDEFENDER, IBEXIS WEALTHDEFENDER BONUS, and IBEXIS WEALTHDEFENDER BONUS PLUS. The owner is based in WEST PALM BEACH, FL.
700 S ROSEMARY AVE
SUITE 204
WEST PALM BEACH, FL 33401
Showing of trademarks Trademarks
Trademark Classifications
IBEXIS LIFE & ANNUITY INSURANCE COMPANY's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does IBEXIS LIFE & ANNUITY INSURANCE COMPANY have?
IBEXIS LIFE & ANNUITY INSURANCE COMPANY has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.
What trademark classes does IBEXIS LIFE & ANNUITY INSURANCE COMPANY file in?
IBEXIS LIFE & ANNUITY INSURANCE COMPANY files trademarks across 1 Nice Classification class. The most active classes are Class 36 (Insurance & Financial). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are IBEXIS LIFE & ANNUITY INSURANCE COMPANY's most well-known trademarks?
IBEXIS LIFE & ANNUITY INSURANCE COMPANY's registered trademark portfolio includes well-known marks such as IBEXIS, IBEXIS FIA PLUS, IBEXIS WEALTHDEFENDER, IBEXIS WEALTHDEFENDER BONUS, and IBEXIS WEALTHDEFENDER BONUS PLUS. These are among 6 currently registered trademarks in the portfolio.
What is IBEXIS LIFE & ANNUITY INSURANCE COMPANY's trademark registration success rate?
IBEXIS LIFE & ANNUITY INSURANCE COMPANY has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.